Background: The purpose of this study was to investigate if Sonazoid-enhanced harmonic ultrasonography (US) could be used to evaluate the responses of hepatocellular carcinomas (HCCs) to treatment with transcatheter arterial chemoembolization (TACE). Patients and Methods: Forty-three HCCs that had been treated by TACE were evaluated by Sonazoid-enhanced harmonic US and dynamic computed tomography (CT) approximately 1 week after their treatment. The detection rates of residual tumor blood supply using the two modalities were compared. Two months after chemoembolization, 16 of the 43 HCCs, which had no additional local treatment, were followed up with dynamic CT. The results of contrast-enhanced harmonic US and dynamic CT 1 week after chemoembolization were analyzed and compared with follow-up dynamic CT results. Results: The detection rates of positive enhancement with Sonazoid-enhanced harmonic US and dynamic CT 1 week after TACE were 25 (58.1%) of 43 lesions and 17 (39.5%) of 43 lesions, respectively. Sonazoid-enhanced harmonic US was significantly more sensitive than dynamic CT in depicting the residual tumor blood supply to HCCs 1 week after TACE (p < 0.01; χ2 test). The Sonazoid-enhanced harmonic US results of the 16 lesions 1 week after chemoembolization were consistent with the follow-up results of dynamic CT 2 months after chemoembolization. Conclusions: Sonazoid-enhanced harmonic US appears to be a highly sensitive and accurate modality for evaluating responses of HCCs shortly after TACE.

Keywords:
Hepatocellular carcinoma, Transcatheter arterial chemoembolization, Sonazoid, Sonazoid-enhanced harmonic ultrasonography
1.
Bruix J, Llovet JM: Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519–524.
2.
Yuen MF, Cheng CC, Lauder IJ, et al: Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000;31:330–335.
3.
Llovet JM, Real MI, Montana X, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734–1739.
4.
Morimoto M, Shirato K, Sugimori K, et al: Contrast-enhanced harmonic gray-scale sonographic-histologic correlation of the therapeutic effects of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. AJR Am J Roentgenol 2003;181:65–69.
5.
Numata K, Tanaka K, Kiba T, et al: Using contrast-enhanced sonography to assess the effectiveness of transcatheter arterial embolization for hepatocellular carcinoma. AJR Am J Roentgenol 2001;176:1199–1205.
6.
Bartolozzi C, Lencioni R, Caramella D, et al: Hepatocellular carcinoma: CT and MR features after transcatheter arterial embolization and percutaneous ethanol injection. Radiology 1994;191:123–128.
7.
Okusaka T, Okada S, Ueno H, et al: Evaluation of the therapeutic effect of transcatheter arterial embolization for hepatocellular carcinoma. Oncology 2000;58:293–299.
8.
Minami Y, Kudo M, Kawasaki T, et al: Transcatheter arterial chemoembolization of hepatocellular carcinoma: usefulness of coded phase-inversion harmonic sonography. AJR Am J Roentgenol 2003;180:703–708.
9.
Ding H, Kudo M, Onda H, et al: Contrast-enhanced subtraction harmonic sonography for evaluating treatment response in patients with hepatocellular carcinoma. AJR Am J Roentgenol 2001;176:661–666.
10.
Watanabe R, Matsumura M, Munemasa T, et al: Mechanism of hepatic parenchyma-specific contrast of microbubble-based contrast agent for ultrasonography: microscopic studies in rat liver. Invest Radiol 2007;42:643–651.
11.
Hatanaka K, Kudo M, Minami Y, et al: Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid. Intervirology 2008;51:S61–S69.
12.
Kudo M, Hatanaka K, Maekawa K: Sonazoid-enhanced ultrasound in the diagnosis and treatment of hepatic tumors. J Med Ultrasound 2008;16:130–139.
13.
Yamada R, Sato M, Kawabata M, et al: Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983;148:397–401.
14.
Takayasu K, Shima Y, Muramatsu Y, et al: Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 1987;163:345–351.
15.
Uchida H, Ohishi H, Matsuo N, et al: Transcatheter hepatic segmental arterial embolization using Lipiodol mixed with an anticancer drug and Gelfoam particles for hepatocellular carcinoma. Cardiovasc Intervent Radiol 1990;13:140–145.
16.
Matsui O, Kadoya M, Yoshikawa J, et al: Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 1993;188:79–83.
17.
Takayasu K, Arii S, Matsuo N, et al: Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR Am J Roentgenol 2000;175:699–704.
18.
Saccheri S, Lovaria A, Sangiovanni A, et al: Segmental transcatheter arterial chemoembolization treatment in patients with cirrhosis and inoperable hepatocellular carcinomas. J Vasc Interv Radiol 2002;13:995–999.
19.
Ito K, Honjo K, Fujita T, et al: Therapeutic efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma: MRI and pathology. J Comput Assist Tomogr 1995;19:198–203.
20.
Lencioni R, Caramella D, Bartolozzi C: Response of hepatocellular carcinoma to percutaneous ethanol injection: CT and MR evaluation. J Comput Assist Tomogr 1993;17:723–729.
21.
Kubota K, Hisa N, Nishikawa T, et al: Evaluation of hepatocellular carcinoma after treatment with transcatheter arterial chemoembolization: comparison of Lipiodol-CT, power Doppler sonography, and dynamic MRI. Abdom Imaging 2001;26:184–190.
22.
Sontum PC, Ostensen J, Dyrstad K, et al: Acoustic properties of NC100100 and their relation with the microbubble size distribution. Invest Radiol 1999;34:268–275.
23.
Marelli C: Preliminary experience with NC100100, a new ultrasound contrast agent for intravenous injection. Eur Radiol 1999;9(suppl 3):343–346.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.